Early initiation of glecaprevir/pibrentasvir after transplantation of HCV‐viremic kidneys into HCV‐negative recipients is associated with normalization in the altered inflammatory milieu
Clinical Transplantation · 2023
DOI: 10.1111/ctr.14926 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Transplantation, 2023. Verfasst von Myung-Ho Kim und 12 weiteren Autor:innen. Beteiligte Einrichtung: Liver Center, Gastrointestinal Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Hepatitis C. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Our previous Multicenter Trial to Transplant HCV‐infected Kidneys (MYTHIC) observed that 100% of hepatitis C virus (HCV)‐uninfected patients who received a kidney from an HCV‐infected deceased donor were cured of HCV with an 8‐week regimen of glecaprevir and pibrentasvir (G/P) initiated 2–5 days after transplantation. Following acute and chronic infection with HCV, immune system perturbations have been reported to persist even after viral clearance. The aim of this study was to determine whether HCV viremic kidney recipients in the MYTHIC study experience sustained changes in the soluble inflammatory milieu associated with HCV infection. Among nine patients with HCV viremia at day 3 post‐kidney transplant (post‐KT D3), IP‐10, IL‐10, MIP‐1β, and IL‐8 were significantly elevated from baseline. However, over the subsequent visits, there was a rapid, dramatic reduction back to baseline levels. Among seven patients who were not HCV viremic at post‐KT D3, the cytokine levels did not significantly change. HCV‐uninfected patients who received a kidney from an HCV‐viremic deceased donor and were treated with early G/P experienced only transient alterations in the soluble inflammatory milieu. These data provide reassuring evidence that there appear to be no persistent cytokine disturbances with transient HCV viremia accompanying HCV donor positive/recipient negative kidney transplant.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liver Center, Gastrointestinal Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Nephrology Division, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Division of Digestive Health & Liver Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA.
- Division of Gastroenterology & Hepatology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
- Global Medical Affairs Research & Development, AbbVie Inc., North Chicago, Illinois, USA.
- Division of Nephrology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
ORCID-Profile: Myung-Ho Kim
Förderung
- NIDDK NIH HHS
Zitieren
APA
Kim, M. H., Sise, M. E., Xu, M., Goldberg, D. S., Fontana, R. J., Kort, J. J., Alloway, R. R., Durand, C. M., Brown, R. S., Levitsky, J., Gustafson, J. L., Reese, P. P., & Chung, R. T. (2023). Early initiation of glecaprevir/pibrentasvir after transplantation of HCV‐viremic kidneys into HCV‐negative recipients is associated with normalization in the altered inflammatory milieu. Clinical Transplantation. https://doi.org/10.1111/ctr.14926
Vancouver
Kim MH, Sise ME, Xu M, Goldberg DS, Fontana RJ, Kort JJ, et al. Early initiation of glecaprevir/pibrentasvir after transplantation of HCV‐viremic kidneys into HCV‐negative recipients is associated with normalization in the altered inflammatory milieu. Clinical Transplantation. 2023. doi:10.1111/ctr.14926
BibTeX
@article{Kim2023,
author = {Kim, Myung-Ho and Sise, Meghan E and Xu, Min and Goldberg, David S and Fontana, Robert J and Kort, Jens J and Alloway, Rita R and Durand, Christine M and Brown, Robert S and Levitsky, Josh and Gustafson, Jenna L and Reese, Peter P and Chung, Raymond T},
title = {Early initiation of glecaprevir/pibrentasvir after transplantation of HCV‐viremic kidneys into HCV‐negative recipients is associated with normalization in the altered inflammatory milieu},
journal = {Clinical Transplantation},
year = {2023},
doi = {10.1111/ctr.14926}
}
EUVIMED